Skip to main content

Table 4 Associations between TDP-43 and arteriolosclerosis (moderate/severe vs. none/mild) pathologies among included subjects stratified by APOE genotype

From: Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer’s disease and cerebrovascular disease pathologies

Region APOE −/− or −/ε4
(n = 679)a
APOE ε4/ε4
(n = 76)a
OR (95% CI) P-value OR (95% CI) P-value
Model 1b
 Amygdala 1.66 (1.07–2.59) 0.023 0.71 (0.16–3.19) 0.65
 Hippocampus 1.40 (0.96–2.05) 0.083 0.89 (0.29–2.79) 0.84
 EC/inferior TCTX 1.82 (1.18–2.86) 0.0080 1.43 (0.35–6.55) 0.62
 Frontal neocortex 1.13 (0.50–2.61) 0.76 0.26 (0.01–3.04) 0.30
Model 2c
 Amygdala 1.43 (0.91–2.26) 0.12 0.57 (0.12–2.67) 0.47
 Hippocampus 1.19 (0.80–1.77) 0.39 0.80 (0.25–2.56) 0.70
 EC/inferior TCTX 1.60 (1.02–2.54) 0.041 1.13 (0.27–5.26) 0.87
 Frontal neocortex 1.08 (0.47–2.52) 0.86 0.21 (0.01–2.47) 0.23
  1. aA total of 755 subjects had data on APOE genotype (those data were missing in 174 subjects)
  2. bOdds ratios were adjusted for sex, age at death, and the type of TDP-43 antibody used
  3. cThal Aβ phase and Braak NFT stage were included as additional covariates in model 2
  4. OR odds ratio, CI confidence interval, EC entorhinal cortex, TCTX temporal cortex
  5. Bold p-value represents the statistical significance